Last checked at 17 May 2019 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Notice of AGM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the Annual General Meeting will be held on 11 June 2019 at 3pm at Foxhills Country Club, Stonehill Road, Ottershaw, Surrey KT16 0EL.
A copy of the notice of AGM will be available on the Company's website today.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Stephen O'Hara, Chief Executive | Contact via Walbrook below | |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner | ||
finnCap (Broker) |
Tel: 020 7220 0500 | |
Geoff Nash / Kate Bannatyne (Corporate Finance) | ||
Camille Gochez (Corporate Broking) | ||
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com | |
Anna Dunphy | Mob: 07876 741 001 | |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.